Eli Lilly and Company (LLY), Monday announced a deal with Ajax Therapeutics, Inc., agreeing to acquire the company along with its lead asset, AJ1-11095, an investigational, once-daily oral, first-in-class Type II JAK2 inhibitor currently being evaluated in patients with myelofibrosis.
As per the deal, Ajax shareholders would receive up to $2.3 billion in cash, inclusive of an upfront payment and subsequent payments upon the achievement of certain clinical and regulatory milestones.
"As a founding strategic investor in Ajax, Lilly has long believed in the approach and is excited about the potential for AJ1-11095 to deliver deeper and more durable efficacy than available treatments with a tolerability profile that would allow for patients to remain on therapy longer and be used across both the first- and second-line settings," said Jacob Van Naarden, executive vice president and president of Lilly Oncology and head of corporate business development.
In the pre-market hours, LLY is trading at $884.65, up 0.05 percent on the New York Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.